TPWA
CPRX

Twin Peaks Wealth Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.49K Buy
+343
New +$8.17K ﹤0.01% 1145
2025
Q3 		– Sell
-196
Closed -$3.99K – 573
2025
Q2 		$3.99K Buy
+196
New +$4.63K ﹤0.01% 1405

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Twin Peaks Wealth Advisors's CPRX Position: Q1 2026 in Review

Twin Peaks Wealth Advisors opened a new position in Catalyst Pharmaceutical (CPRX) in Q1 2026: 343 shares worth $8.49K. The stake represents ﹤0.01% of the portfolio and ranks #1145 among its holdings. This is a return to the name: Twin Peaks Wealth Advisors previously reported a position in CPRX as recently as Q2 2025.

Twin Peaks Wealth Advisors first reported a position in CPRX in Q2 2025 and has held it in 2 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Twin Peaks Wealth Advisors held 343 shares of Catalyst Pharmaceutical worth $8.49K as of Q1 2026.
  • Catalyst Pharmaceutical was a new Twin Peaks Wealth Advisors position in Q1 2026.
  • Catalyst Pharmaceutical made up ﹤0.01% of Twin Peaks Wealth Advisors's portfolio in Q1 2026, its #1145 holding.
  • Twin Peaks Wealth Advisors first reported a position in Catalyst Pharmaceutical in Q2 2025 and has held it in 2 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q1 2026, filed 8 May 2026.